Bone Density Conservation Agents
"Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
| Descriptor ID |
D050071
|
| MeSH Number(s) |
D27.505.696.242
|
| Concept/Terms |
Antiresorptive Agents- Antiresorptive Agents
- Bone Resorption Inhibitors
- Inhibitors, Bone Resorption
- Resorption Inhibitors, Bone
- Bone Resorption Inhibitory Agents
- Antiresorptive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Bone Density Conservation Agents".
Below are MeSH descriptors whose meaning is more specific than "Bone Density Conservation Agents".
This graph shows the total number of publications written about "Bone Density Conservation Agents" by people in this website by year, and whether "Bone Density Conservation Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 2 | 6 |
| 2007 | 6 | 5 | 11 |
| 2008 | 13 | 5 | 18 |
| 2009 | 3 | 3 | 6 |
| 2010 | 3 | 5 | 8 |
| 2011 | 7 | 3 | 10 |
| 2012 | 9 | 4 | 13 |
| 2013 | 9 | 2 | 11 |
| 2014 | 9 | 3 | 12 |
| 2015 | 6 | 0 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 4 | 6 |
| 2018 | 2 | 0 | 2 |
| 2019 | 4 | 2 | 6 |
| 2020 | 5 | 2 | 7 |
| 2021 | 4 | 0 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles.
-
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. Eur J Cancer. 2024 Sep; 208:114122.
-
The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature. Spine J. 2024 Jun; 24(6):1056-1064.
-
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis. Clin Breast Cancer. 2023 12; 23(8):e515-e522.
-
Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023 06 16; 108(7):1787-1796.
-
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023 02 15; 108(3):507-528.
-
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocr Pract. 2022 Oct; 28(10):1078-1085.
-
Best Practice Guidelines for Assessment and Management of Osteoporosis in Adult Patients Undergoing Elective Spinal Reconstruction. Spine (Phila Pa 1976). 2022 Jan 15; 47(2):128-135.
-
Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021 12; 50(4):721-728.
-
Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial. Circulation. 2021 06 22; 143(25):2418-2427.
-
Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis. J Pediatr Hematol Oncol. 2021 03 01; 43(2):e215-e218.